You are here: Home » News-CM » Companies » News
Business Standard

USFDA refuses admission to APIs manufactured by Ipca Laboratories

Capital Market 

At its API manufacturing facility at Ratlam (Madhya Pradesh)

has received a communication from USFDA stating that all the drugs manufactured at the Company's API manufacturing facility at Ratlam (Madhya Pradesh) will be henceforth refused admission into United States (except API Chloroquine Phosphate, which will be reconsidered if shortage and/or medical necessity implication change) until the Company can demonstrate that the drugs manufactured at this manufacturing site and intended for the US market are in compliance with cGMP.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

USFDA refuses admission to APIs manufactured by Ipca Laboratories

At its API manufacturing facility at Ratlam (Madhya Pradesh)

At its API manufacturing facility at Ratlam (Madhya Pradesh)

has received a communication from USFDA stating that all the drugs manufactured at the Company's API manufacturing facility at Ratlam (Madhya Pradesh) will be henceforth refused admission into United States (except API Chloroquine Phosphate, which will be reconsidered if shortage and/or medical necessity implication change) until the Company can demonstrate that the drugs manufactured at this manufacturing site and intended for the US market are in compliance with cGMP.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

USFDA refuses admission to APIs manufactured by Ipca Laboratories

At its API manufacturing facility at Ratlam (Madhya Pradesh)

has received a communication from USFDA stating that all the drugs manufactured at the Company's API manufacturing facility at Ratlam (Madhya Pradesh) will be henceforth refused admission into United States (except API Chloroquine Phosphate, which will be reconsidered if shortage and/or medical necessity implication change) until the Company can demonstrate that the drugs manufactured at this manufacturing site and intended for the US market are in compliance with cGMP.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22